Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic

Jing Li, Ju Liu, Xuemei Zhang, Valerie Clausen, Chris Tran, Michael Arciprete, Qianfan Wang, Carrie Rocca, Li-Hua Guan, Guodong Zhang, Diana Najarian, Yuanxin Xu, Peter Smith, Jing-Tao Wu and Saeho Chong
Drug Metabolism and Disposition July 2021, 49 (7) 572-580; DOI: https://doi.org/10.1124/dmd.121.000381
Jing Li
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ju Liu
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xuemei Zhang
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valerie Clausen
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris Tran
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Arciprete
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianfan Wang
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carrie Rocca
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li-Hua Guan
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guodong Zhang
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Najarian
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuanxin Xu
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Smith
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing-Tao Wu
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saeho Chong
Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 49 no. 7 572-580
DOI 
https://doi.org/10.1124/dmd.121.000381
PubMed 
33941543

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received January 19, 2021
  • Accepted April 19, 2021
  • Published online July 16, 2021.

Article Versions

  • Earlier version (May 3, 2021 - 13:18).
  • Earlier version (May 4, 2021 - 13:08).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Jing Li,
  2. Ju Liu,
  3. Xuemei Zhang,
  4. Valerie Clausen,
  5. Chris Tran,
  6. Michael Arciprete,
  7. Qianfan Wang,
  8. Carrie Rocca,
  9. Li-Hua Guan,
  10. Guodong Zhang,
  11. Diana Najarian,
  12. Yuanxin Xu,
  13. Peter Smith,
  14. Jing-Tao Wu, and
  15. Saeho Chong
  1. Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts
  1. Address correspondence to:
    Saeho Chong, Drug Metabolism and Pharmacokinetics, Early Development, Alnylam Pharmaceuticals, 675 W Kendall St., Cambridge, Massachusetts 02142. E-mail: schong{at}alnylam.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: May 2021 to May 2022

AbstractFullPdf
May 2021115312343
Jun 20217420172
Jul 202167753142
Aug 202132661104
Sep 20213582077
Oct 20214643580
Nov 20212923380
Dec 20212822276
Jan 20222412279
Feb 20222493455
Mar 20222002242
Apr 20222163185
May 20221801636

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 49 (7)
Drug Metabolism and Disposition
Vol. 49, Issue 7
1 Jul 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Nonclinical PK and ADME of Givosiran

Jing Li, Ju Liu, Xuemei Zhang, Valerie Clausen, Chris Tran, Michael Arciprete, Qianfan Wang, Carrie Rocca, Li-Hua Guan, Guodong Zhang, Diana Najarian, Yuanxin Xu, Peter Smith, Jing-Tao Wu and Saeho Chong
Drug Metabolism and Disposition July 1, 2021, 49 (7) 572-580; DOI: https://doi.org/10.1124/dmd.121.000381

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Nonclinical PK and ADME of Givosiran

Jing Li, Ju Liu, Xuemei Zhang, Valerie Clausen, Chris Tran, Michael Arciprete, Qianfan Wang, Carrie Rocca, Li-Hua Guan, Guodong Zhang, Diana Najarian, Yuanxin Xu, Peter Smith, Jing-Tao Wu and Saeho Chong
Drug Metabolism and Disposition July 1, 2021, 49 (7) 572-580; DOI: https://doi.org/10.1124/dmd.121.000381
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Determination of Acyl-, O-, and N-Glucuronide
  • TMDD Affects PK of IL-10 Fc-fusion Proteins
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics